title: Cardiovascular risk markers and mechanisms in targeting the COX pathway for colorectal cancer prevention.
abstract: COX-2 inhibition reduces the incidence of colorectal neoplasia. The increased risk of thrombotic cardiovascular events produced by selective or nonselective COX-2 inhibitors, however, has confounded the consideration of employing them in cancer prevention. Developing a strategy for preventing colorectal cancer by inhibiting COX-2 depends on research advances in several key areas, including predictive biomarkers to identify people at the lowest risk for cardiovascular events, the molecular mechanisms whereby interdicting the COX-2 pathway produces thrombotic events, and the pharmacology of the widely divergent agents that act on COX-2 and its downstream pathway.
authors.affiliation: Vanderbilt University School of Medicine, Nashville, Tennessee, USA. oates@vanderbilt.edu
authors.forename: John A
authors.initials: JA
authors.lastname: Oates
mesh_terms: D000236:Adenoma / Q000378:metabolism*; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002097:C-Reactive Protein / Q000096:biosynthesis*; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D011720:Pyrazoles / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*
chemical_list: D016588:Anticarcinogenic Agents; D011720:Pyrazoles; D013449:Sulfonamides; D002097:C-Reactive Protein; D000068579:Celecoxib